TY - JOUR
T1 - Adjunctive Glaucoma Therapy
T2 - A Comparison of Apraclonidine to Dipivefrin when Added to Timolol Maleate
AU - Morrison, John C.
AU - Robin, Alan L.
N1 - Funding Information:
Supported in part by grants from Alcon Laboratories, Fort Worth, Texas, and National Eye Institute NRSA institutional training grant EY07047 (Dr. Morrison).
PY - 1989
Y1 - 1989
N2 - The authors compared the additive intraocular pressure (IOP)-lowering effects of two different topical medications, apraclonidine hydrochloride and dipivefrin hydrochloride, when used in conjunction with timolol maleate. Eighteen patients with elevated IOPs entered a randomized, double-masked, cross-over study. Each used apraclonidine 1.0%, dipivefrin 0.1 %, or placebo, twice daily for 3 weeks each, in addition to timolol 0.5% twice daily. Only apraclonidine produced a significant additional IOP lowering over timolol treatment alone at all time intervals (P < 0.001). Its additive effect was significantly greater than that seen with dipivefrin at all time intervals (P < 0.01), with the exception of day 22 (P = 0.061). No significant change in pulse rate or blood pressure was seen during apraclonidine administration. Apraclonidine may be a useful adjunctive agent in patients with poorly controlled glaucoma.
AB - The authors compared the additive intraocular pressure (IOP)-lowering effects of two different topical medications, apraclonidine hydrochloride and dipivefrin hydrochloride, when used in conjunction with timolol maleate. Eighteen patients with elevated IOPs entered a randomized, double-masked, cross-over study. Each used apraclonidine 1.0%, dipivefrin 0.1 %, or placebo, twice daily for 3 weeks each, in addition to timolol 0.5% twice daily. Only apraclonidine produced a significant additional IOP lowering over timolol treatment alone at all time intervals (P < 0.001). Its additive effect was significantly greater than that seen with dipivefrin at all time intervals (P < 0.01), with the exception of day 22 (P = 0.061). No significant change in pulse rate or blood pressure was seen during apraclonidine administration. Apraclonidine may be a useful adjunctive agent in patients with poorly controlled glaucoma.
UR - http://www.scopus.com/inward/record.url?scp=0024592143&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024592143&partnerID=8YFLogxK
U2 - 10.1016/S0161-6420(89)32943-5
DO - 10.1016/S0161-6420(89)32943-5
M3 - Article
C2 - 2645550
AN - SCOPUS:0024592143
SN - 0161-6420
VL - 96
SP - 3
EP - 7
JO - Ophthalmology
JF - Ophthalmology
IS - 1
ER -